This research proposes a novel mechanism of TAM reprogramming through the LINC00330/CCL2 axis, offering a potential avenue for targeted and combination immunotherapy strategies for the treatment of ESCC patients. This evidence concerns the gene LINC00330 and esophageal squamous cell carcinoma.